Jimmy Bell
Adult Health · Rolla, MONPI 1447305412
Payments from drug & device makers
Across 298 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$788
- Amgen$715
- Novo Nordisk$547
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$503
- Lilly USA, LLC$333
- Otsuka America Pharmaceutical, Inc.$292
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,75298%
- Education$822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $788 |
| Amgen | 52 | $715 |
| Novo Nordisk | 27 | $547 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 37 | $503 |
| Lilly USA, LLC | 13 | $333 |
| Otsuka America Pharmaceutical, Inc. | 17 | $292 |
| Lundbeck LLC | 13 | $258 |
| AstraZeneca | 14 | $224 |
| GSK | 20 | $189 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $164 |
| Sanofi-aventis U.S. LLC | 5 | $114 |
| Pfizer | 7 | $104 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Exact Sciences | 3 | $56 |
| Boehringer Ingelheim | 3 | $54 |
| Merck | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Ardelyx, Inc. | 2 | $38 |
| Abbott | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Apria Healthcare LLC | 1 | $25 |
| Sanofi | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| UCB, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Philips North America LLC | 1 | $19 |
| Bayer | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$115
How this compares
$4,833 in reported general payments places this provider in the 85th percentile of 555 adult health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $130,809 |
| XareltoRivaroxaban | 96 | $91,838 |
| JardianceEmpagliflozin | 112 | $90,745 |
| EliquisApixaban | 113 | $77,163 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 122 | $71,716 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $33,722 |
| MounjaroTirzepatide | 27 | $30,165 |
| FarxigaDapagliflozin Propanediol | 45 | $27,159 |
| TrulicityDulaglutide | 30 | $27,123 |
| LinzessLinaclotide | 46 | $25,240 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $23,608 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $19,224 |
| Repatha SureclickEvolocumab | 28 | $16,550 |
| QuliptaAtogepant | 13 | $15,745 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $13,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $547 | $130,809112 claims |
| Boehringer IngelheimJardiance | $54 | $90,745112 claims |
| PfizerEliquis | $104 | $77,163113 claims |
| Lilly USA, LLCMounjaro, Trulicity | $333 | $57,28857 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta | $189 | $47,64980 claims |
| AstraZenecaFarxiga, Nexium, Symbicort | $224 | $44,47585 claims |
| AbbVieLinzess, Qulipta | $788 | $40,98559 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $114 | $24,58837 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $49 | $10,74122 claims |
| MerckJanuvia | $53 | $8,33315 claims |
| NovartisEntresto | $12 | $7,55611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 555 adult health providers in Missouri.
Other adult health in Rolla
- Tabitha StithChesterfield$300K
- Stephanie VogelSaint Louis$115K
- Racquel FrisellaChesterfield$110K
- Shannon TuckerSaint Louis$93K
- Laurencia KlipfelSaint Louis$79K
- Maria WallsSaint Louis$69K
- Katie MurrayIndependence$59K
- Patrick BehnkeChesterfield$54K
- Elaine ZobristFenton$38K
- Yolanda Thompson MartinKansas City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.